AI-generated summary
The authors studied whether daily extraoral photobiomodulation therapy could be delivered to children undergoing hematopoietic cell transplantation to help prevent oral mucositis. In 13 enrolled patients, the authors report that the therapy was feasible, with 96.2 percent of days having data submitted and no reported toxicity attributed to the treatment. The study was a small feasibility study, so it does not test whether the therapy prevents mucositis.
- Participants
- 13
- Who or what was studied
- Children and young adults aged 4 to 21 years scheduled for myeloablative hematopoietic cell transplantation
- Wavelengths
- 660, 850 nm
- Limits stated in the abstract
- The abstract describes a small feasibility study with 13 patients and does not report a control group or a comparison of mucositis outcomes.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm, 850 nm
- Power
- 10 mW, 30 mW, 1390 mW
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation therapy, Photobiomodulation, Light-emitting diode, Confidence interval, Oral mucositis, Power output, Irradiance, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.